ECSS
CYTK icon

Eurizon Capital SGR SpA’s Cytokinetics CYTK Stock Holding History

Eurizon Capital SGR SpA’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Buy
2,337
+133
+6% +$9.55K ﹤0.01% 742
2026
Q1 		$139K Buy
2,204
+133
+6% +$8.45K ﹤0.01% 815
2025
Q4 		$127K Buy
+2,071
New +$129K ﹤0.01% 731

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eurizon Capital SGR SpA's CYTK Position: Q2 2026 in Review

Eurizon Capital SGR SpA increased its Cytokinetics (CYTK) stake by 6% in Q2 2026, buying an estimated $9.55K and bringing the position to 2,337 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #742.

Eurizon Capital SGR SpA first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Eurizon Capital SGR SpA held 2,337 shares of Cytokinetics worth $204K as of Q2 2026.
  • Eurizon Capital SGR SpA bought 133 Cytokinetics shares in Q2 2026, an estimated $9.55K.
  • Cytokinetics made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #742 holding.
  • Eurizon Capital SGR SpA first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.